Antibodies that block inhibitory immune checkpoints, such as PD-1, programmed cell death ligand 1 (PD-L1), enhance the killing capacity of T cells against cancer cells, have achieved significant therapeutic effects in cancers, especially lung cancer and melanoma [4–6]. This evidence concerns the gene CD274 and cancer.